CClinicalTrials.gg
CompletedNCT03166202Updated Jun 6, 2019

Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator

An observational study in Age-related Macular Degeneration, sponsored by University of Alabama at Birmingham. Completed at 1 site in United States. Open to participants aged 60 Years to 95 Years. Per ClinicalTrials.gov, last updated 2019-06-06.

Sponsored by University of Alabama at Birmingham · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
40
Ages
60 Years to 95 Years
Sex
All
01

Study summary

Previous work collectively suggests that rod-mediated dark adaptation (RMDA) is a promising candidate as a functional endpoint measure for evaluating interventions to slow early progression of age-related macular degeneration (AMD). However, there is no agreement among the clinical, research and regulatory communities as to what constitutes a clinically (practically) significant slowing in RMDA. Treatments for AMD are often not considered efficacious if they do not result in a criterion level of improvement in vision. But how much change in the rate of dark adaptation constitutes a clinically significant change? Until this issue is resolved, progress in developing clinical trials on early AMD are at a standstill since there is no functional endpoint to be used in the trial. One approach to establishing clinical significance is to examine how RMDA relates to the performance of an everyday visual task under low luminance conditions, such as night driving or reading. However, such data are not yet available. The purpose of this project is to examine the relationship between RMDA and night-time driving and reading under poor illumination. This information will guide the development of a definition of a clinically significant difference in RMDA that can be used in designing clinical trials on early AMD.

Read the detailed description

The specific aims of this study are as follows:

Aim 1: To examine the association between RMDA as assessed by the rod intercept time and self reported driving difficulty and experiences during night time driving.

Aim 2: To examine the association between RMDA as assessed by rod intercept time and reading performance as assessed by the MNREAD test administered under a low light level. Reading performance will be defined in terms of maximum reading speed, critical print size (i.e., the smallest print size that supports maximum reading speed), reading acuity (i.e., the smallest print size that can be just read) and the reading accessibility index (i.e., an individual's access to text over the range of print sizes found in everyday life).

02

Conditions studied

  • Age-related Macular Degeneration

Keywords

  • age-related macular degeneration
03

In context

Macular Degeneration

1,474 studies on the registry are indexed under Macular Degeneration; 206 are open to participants now.

This study's enrollment of 40 is below the median of 106 across 421 observational studies indexed under Macular Degeneration.

Browse Macular Degeneration studies →

Lead sponsor

University of Alabama at Birmingham is the lead sponsor of 1,396 studies on the registry; 284 are open to participants now.

Of its 156 completed or terminated interventional studies of FDA-regulated products, 124 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults living in the community who have current driver's license who have age-related macular degeneration

Inclusion criteria

  • age-related macular degeneration in one or both eyes, ability to follow simple instructions, licensed to drive a vehicle, can read and speak English

Exclusion criteria

Exclusion Criteria:

  • diabetes, retinal or optic nerve conditions other than age-related macular degeneration, neurological conditions that impair vision
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
40 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. rod intercept time

    rate of rod-mediated dark adaptation

    Time frame: measured once (1 day)

Secondary outcomes

  1. severity of age-related macular degeneration

    defined by grading of color fundus photos

    Time frame: measured once (1 day)

07

Study locations

1 site
  • Callahan Eye Hospital, UAB Dept of Ophthalmolog & Visual Sciences
    Birmingham, Alabama 35294-0009, United States
08

References and documents

Publications

  • Owsley C, McGwin G Jr, Clark ME, Jackson GR, Callahan MA, Kline LB, Witherspoon CD, Curcio CA. Delayed Rod-Mediated Dark Adaptation Is a Functional Biomarker for Incident Early Age-Related Macular Degeneration. Ophthalmology. 2016 Feb;123(2):344-351. doi: 10.1016/j.ophtha.2015.09.041. Epub 2015 Oct 30. PubMed 26522707 ↗

Individual participant data

Plan to share: Undecided — Once study is completed and published in the peer review literature, we will arrange for a data sharing process with other researchers

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03166202
Lead sponsor
University of Alabama at Birmingham
Responsible party
Cynthia Owsley (Principal Investigator, University of Alabama at Birmingham) — Principal investigator
First posted
May 25, 2017
Start date
Sep 1, 2018
Primary completion
Mar 5, 2019
Completion
Mar 5, 2019
Last update
Jun 6, 2019

Study contacts

Cynthia Owsley, PhD
principal investigator · University of Alabama at Birmingham
MiYoung Kwon, PhD
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion